Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials.
The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer diagnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality: the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Eckersberger
Elisabeth
E
Department of Urology, School of Medicine, New York University New York, NY.
Finkelstein
Julia
J
Sadri
Helen
H
Margreiter
Markus
M
Taneja
Samir S
SS
Lepor
Herbert
H
Djavan
Bob
B